The Patent Trolls Are Coming...To Medtech
For years medical device makers have largely avoided one of the technology world’s biggest headaches: patent “troll” litigation, but that’s about to change. What medtech needs to do to fight the trolls.
You may also be interested in...
Biotechnology Industry Organization throws support behind Senate bill’s revisions to the inter partes review process, argues against provisions in House measure.
Counsels’ view of what inter parte reviews and other new procedures introduced by the America Invents Act mean to the biopharma industry.
Non-practicing entities have a few characteristics that create an uneven playing field in patent-infringement lawsuits.